Antihypertensive efficacy of the ACE-inhibitor perindopril in the elderly

Fh, Leenen; Tanner, Joanna; Cf, McNally

doi:10.1038/sj.jhh.1001004

Cited by 5 publications

(1 citation statement)

References 13 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…1), is a nonsulfhydryl angiotensin-converting enzyme inhibitor. PDE is used in the treatment of hypertensive patients with heart failure, post myocardial infarction, high coronary disease risk, diabetes mellitus, chronic renal failure, and/or cerebrovascular disease Hurst and Jarvis, 2001;Jastrzebskal et al, 2004;Leenen et al, 2000).…”

Section: Introductionmentioning

confidence: 99%

Determination of Angiotensin-Converting Enzyme Inhibitor, Perindopril Erbumine, in Bulk and Tablet Dosage Form with HPLC

Nagalakshmi¹

2012

ACSJ

View full text Add to dashboard Cite

show abstract

Section: Introductionmentioning

confidence: 99%

Determination of Angiotensin-Converting Enzyme Inhibitor, Perindopril Erbumine, in Bulk and Tablet Dosage Form with HPLC

Nagalakshmi¹

2012

ACSJ

View full text Add to dashboard Cite

show abstract

A Systematic Literature Review and Network Meta-analysis of Azilsartan Medoxomil Compared to Other Anti-hypertensives Efficacy in Lowering Blood Pressure Amongst Mild to Moderate Hypertensive Patients

Qian,

Zhang,

Chen

2024

Adv Ther

View full text Add to dashboard Cite

Introduction A systematic literature review and network meta-analysis was conducted on azilsartan medoxomil (AZL-M) versus other antihypertensive drugs’ efficacy in hypertensive patients. Methods The search utilized English platforms, from January 2000 until December 2023, resulting in 10,380 articles being screened. Screening criteria included hypertension (mild or moderate); first-line treatment and washout periods; studies (monotherapy) with AZL-M, angiotensin type II receptor blockers (ARBs), angiotensin-converting enzyme inhibitors (ACEIs), angiotensin receptor neprilysin inhibitor (ARNIs), beta-blockers, calcium channel blockers (CCBs), and diuretics, either as intervention or comparator; and antihypertension efficacy as an outcome measure. Study design was randomized clinical trials. Efficacy variables included absolute office systolic and diastolic blood pressure (BP) reductions. A total of 21 publications provided adequate data for analysis, of which 20 studies reported both systolic and diastolic BP and one study reported only the diastolic BP. Results In 21 studies on systolic BP, against the common comparator placebo, the differences in systolic BP were significantly in favor of AZL-M, amlodipine, candesartan, irbesartan, nebivolol, nifedipine, olmesartan, sacubitril valsartan, telmisartan, and valsartan. The surface under the cumulative ranking curve (SUCRA) ranking shows that AZL-M 80 mg had the highest ranking, with a possibility of 93% being the best in all other included treatments. In 20 studies on diastolic BP, against the common comparator placebo, the differences in diastolic BP were significantly in favor of AZL-M, amlodipine, bisoprolol, nebivolol, olmesartan, sacubitril valsartan, telmisartan, and valsartan. The SUCRA ranking shows that AZL-M 80 mg had the highest ranking, with a possibility of 90% being the best in all other included treatments. Conclusion AZL-M at 40 mg and 80 mg shows favorable efficacy compared to other anti-hypertensives, and the 80 mg dosage seemed to be the most efficacious of all the included treatments in reducing both office systolic and diastolic BP in patients with mild-to-moderate hypertension. Supplementary Information The online version contains supplementary material available at 10.1007/s12325-024-02997-5.

show abstract

Dysphonia Secondary to Perindopril Treatment

Vázquez

2003

American Journal of Hypertension

View full text Add to dashboard Cite

Antihypertensive efficacy of the ACE-inhibitor perindopril in the elderly

Cited by 5 publications

References 13 publications

Determination of Angiotensin-Converting Enzyme Inhibitor, Perindopril Erbumine, in Bulk and Tablet Dosage Form with HPLC

Determination of Angiotensin-Converting Enzyme Inhibitor, Perindopril Erbumine, in Bulk and Tablet Dosage Form with HPLC

A Systematic Literature Review and Network Meta-analysis of Azilsartan Medoxomil Compared to Other Anti-hypertensives Efficacy in Lowering Blood Pressure Amongst Mild to Moderate Hypertensive Patients

Dysphonia Secondary to Perindopril Treatment

Contact Info

Product

Resources

About